Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amur Minerals ( (GB:CRTX) ) has shared an update.
CRISM Therapeutics Corporation has submitted an application to the FDA for Orphan Drug Designation for its irinotecan-ChemoSeed™ aimed at treating glioblastoma, a rare and aggressive brain cancer. This move is part of CRISM’s broader strategy to gain accelerated development and market access in the US and UK, leveraging the benefits of ODD status, which include market exclusivity and regulatory support. The company is also preparing for a Phase 2 clinical trial and exploring global regulatory collaborations to expedite access to its promising cancer treatment.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage drug delivery company specializing in the localized and sustained delivery of chemotherapy drugs to improve the treatment of solid tumors. Its lead product, ChemoSeed, is designed to be implanted directly into tumors or resection margins to ensure effective delivery of chemotherapy, particularly in challenging cases like glioblastoma where traditional methods struggle due to the blood-brain barrier.
Average Trading Volume: 65,255
Technical Sentiment Signal: Sell
Current Market Cap: £4.2M
See more insights into CRTX stock on TipRanks’ Stock Analysis page.